2024

Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. PMID: 37871309; PMCID: PMC10827405.

Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 February 1;30(3):586-599. PubMed PMID: 37992313; PubMed Central PMCID: PMC10831334; DOI: 10.1158/1078- 0432.CCR-23-0163.

Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernandez-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer discovery. 2024 January 12. PubMed PMID: 38230747; DOI: 10.1158/2159-8290.CD-22-0952.

Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, Um JS, Tanaka K, Cai W, Yoo S, Dunbar A, Park Y, McAvoy D, Hosszu KK, Levine RL, Boelens JJ, Lorenz IC, Brentjens RJ, Daniyan AF. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024 May 20;12(5):e009013. doi: 10.1136/jitc-2024-009013. PMID: 38772686; PMCID: PMC11110598.

Gobbo F, Martelli F, Di Virgilio A, Demaria E, Sarli G, Migliaccio AR. The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. Int J Mol Sci. 2024 Jul 13;25(14):7703. doi: 10.3390/ijms25147703. PMID: 39062946; PMCID: PMC11277099.

Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, Stahl M, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, Scandura JM, Marcellino B, Levine RL, Landau DA. Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. Epub 2024 May 8. PMID: 38720070; PMCID: PMC11139586.

Langlais B, Dueck AC, Kosiorek HE, Mead-Harvey C, Meek E, Rogak L, Mascarenhas J, Mesa R, Gowin K, Palmer J, Scherber R, Marcellino B, Hoffman R, Mazza GL. Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms. Leuk Lymphoma. 2024 Oct;65(10):1465-1473. doi: 10.1080/10428194.2024.2356058. Epub 2024 Jun 2. PMID: 38824647; PMCID: PMC11444902.

Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell Rep. 2024 Jan 23;43(1):113608. doi: 10.1016/j.celrep.2023.113608. Epub 2023 Dec 20. PMID: 38117649; PMCID: PMC10828549.

2023

Arciprete F, Verachi P, Martelli F, Valeri M, Balliu M, Guglielmelli P, Vannucchi AM, Migliaccio AR, Zingariello M. Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis. Exp Hematol. 2023 May;121:30-37. doi: 10.1016/j.exphem.2023.02.003. Epub 2023 Mar 1. PMID: 36863479.

Borate U, Yang F, Press R, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick DC, Juckett L, Norris B, Bucy T, Burd A, Stein EM, Patel P, Baer MR, Stock W, Schiller G, Blum W, Kovacsovics T, Litzow M, Foran J, Heerema NA, Rosenberg L, Marcus S, Yocum A, Stefanos M, Druker B, Byrd JC, Levine RL, Mims A. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 Oct 24;7(20):6048-6054. doi: 10.1182/bloodadvances.2022009008. PMID: 37459200; PMCID: PMC10582272.

Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, Park Y, Karzai A, Xiao W, Zaroogian Z, O'Connor K, Mowla S, Gobbo F, Verachi P, Martelli F, Sarli G, Xia L, Elmansy N, Kleppe M, Chen Z, Xiao Y, McGovern E, Snyder J, Krishnan A, Hill C, Cordner K, Zouak A, Salama ME, Yohai J, Tucker E, Chen J, Zhou J, McConnell T, Migliaccio AR, Koche R, Rampal R, Fan R, Levine RL, Hoffman R. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023 May 18;141(20):2508-2519. doi: 10.1182/blood.2022015418. PMID: 36800567; PMCID: PMC10273167.

Foran JM, Sun Z, Lai C, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta E, Lazarus HM, Zhang Y, Bennett JM, Levine RL, Rowe JM, Litzow MR, Tallman MS. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. Cancer. 2023 Aug 15;129(16):2479-2490. doi: 10.1002/cncr.34807. Epub 2023 Apr 25. PMID: 37185873; PMCID: PMC10932613.

Gobbo F, Zingariello M, Verachi P, Falchi M, Arciprete F, Martelli F, Peli A, Mazzarini M, Vierstra J, Mead-Harvey C, Dueck AC, Sarli G, Nava S, Sgalla G, Richeldi L, Migliaccio AR. GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis. bioRxiv [Preprint]. 2023 Sep 19:2023.06.20.542249. doi: 10.1101/2023.06.20.542249. PMID: 37425686; PMCID: PMC10327123.

Gobbo F, Zingariello M, Verachi P, Falchi M, Arciprete F, Martelli F, Peli A, Mazzarini M, Vierstra J, Mead-Harvey C, Dueck AC, Sarli G, Nava S, Sgalla G, Richeldi L, Migliaccio AR. GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis. bioRxiv : the preprint server for biology. 2023 September 19. PubMed PMID: 37425686; PubMed Central PMCID: PMC10327123; DOI: 10.1101/2023.06.20.542249.

Gurska LM, Okabe R, Schurer A, Tong MM, Soto M, Choi D, Ames K, Glushakow-Smith S, Montoya A, Tein E, Miles LA, Cheng H, Hankey-Giblin P, Levine RL, Goel S, Halmos B, Gritsman K. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clin Cancer Res. 2023 Mar 1;29(5):943-956. doi: 10.1158/1078-0432.CCR-22-1763. PMID: 36537918; PMCID: PMC9992133.

Handa S, Ginzburg Y, Hoffman R, Kremyanskaya M. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Curr Opin Hematol. 2023 Mar 1;30(2):45-52. doi: 10.1097/MOH.0000000000000747. Epub 2022 Dec 29. PMID: 36728649; PMCID: PMC9908837.

Marcellino BK, Yang X, Ümit Kaniskan H, Brady C, Chen H, Chen K, Qiu X, Clementelli C, Herschbein L, Li Z, Elghaity-Beckley S, Arandela J, Kelly B, Hoffman R, Liu J, Xiong Y, Jin J, Shih AH. Correction: An MDM2 degrader for treatment of acute leukemias. Leukemia. 2023 Aug;37(8):1764-1765. doi: 10.1038/s41375-023-01934-9. Erratum for: Leukemia. 2023 Feb;37(2):370-378. doi: 10.1038/s41375-022-01735-6. PMID: 37391487.

Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, Mesa R, Rampal RK, Gerds AT, Yacoub A, Pettit K, Talpaz M, Komrokji R, Kremyanskaya M, Gonzalez A, Fabris F, Johnson K, Dougherty M, McGovern E, Arango Ossa J, Domenico D, Farnoud N, Weinberg RS, Kong A, Najfeld V, Vannucchi AM, Arciprete F, Zingariello M, Falchi M, Salama ME, Mead- Harvey C, Dueck A, Varricchio L, Hoffman R. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 September 15;29(18):3622-3632. PubMed PMID: 37439808; PubMed Central PMCID: PMC10502472; DOI: 10.1158/1078-0432.CCR-23-0276.

Mazzarini M, Arciprete F, Picconi O, Valeri M, Verachi P, Martelli F, Migliaccio AR, Falchi M, Zingariello M. Single cell analysis of the localization of the hematopoietic stem cells within the bone marrow architecture identifies niche-specific proliferation dynamics. Front Med (Lausanne). 2023 Apr 28;10:1166758. doi: 10.3389/fmed.2023.1166758. PMID: 37188088; PMCID: PMC10175646.

Saleiro D, Kosciuczuk EM, Fischietti M, Perez RE, Yang GS, Eckerdt F, Beauchamp EM, Hou Y, Wang Q, Weinberg RS, Fish EN, Yue F, Hoffman R, Platanias LC. Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. Cancer Res Commun. 2023 May 31;3(5):943-951. doi: 10.1158/2767-9764.CRC-23-0010. PMID: 37377894; PMCID: PMC10231401.

Shah BN, Zhang X, Sergueeva AI, Miasnikova GY, Ganz T, Prchal JT, Gordeuk VR. Increased transferrin protects from thrombosis in Chuvash erythrocytosis. Am J Hematol. 2023 Oct;98(10):1532-1539. doi: 10.1002/ajh.27021. Epub 2023 Jul 12. PMID: 37435906; PMCID: PMC10529798.

Varricchio L, Geer EB, Martelli F, Mazzarini M, Funnell A, Bieker JJ, Papayannopoulou T, Migliaccio AR. Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis. Haematologica. 2023 Apr 1;108(4):1053-1067. doi: 10.3324/haematol.2021.280542. PMID: 35861015; PMCID: PMC10071118.

Verachi P, Gobbo F, Martelli F, Falchi M, di Virgilio A, Sarli G, Wilke C, Bruederle A, Prahallad A, Arciprete F, Zingariello M, Migliaccio AR. Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model. Exp Hematol. 2023 Jan;117:43-61. doi: 10.1016/j.exphem.2022.09.004. Epub 2022 Oct 1. PMID: 36191885; PMCID: PMC10450205.

Zhang X, Song J, Shah BN, Han J, Hassan T, Miasniakova G, Sergueeva A, Nekhai S, Machado RF, Gladwin MT, Saraf SL, Prchal JT, Gordeuk VR. Gene expression changes in sickle cell reticulocytes and their clinical associations. Sci Rep. 2023 Aug 8;13(1):12864. doi: 10.1038/s41598-023-40039-2. Erratum in: Sci Rep. 2023 Sep 14;13(1):15225. doi: 10.1038/s41598-023-42020-5. PMID: 37553354; PMCID: PMC10409856.

2022

Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14;139(15):2273-2284. doi: 10.1182/blood.2021014309. PMID: 35167654; PMCID: PMC9710485.

Hsieh HH, Yao H, Ma Y, Zhang Y, Xiao X, Stephens H, Wajahat N, Chung SS, Xu L, Xu J, Rampal RK, Huang LJ. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm. Blood. 2022 Dec 1;140(22):2371-2384. doi: 10.1182/blood.2022016741. PMID: 36054916; PMCID: PMC9837451.

King AC, Weis TM, Derkach A, Ball S, Pandey M, Mauro MJ, Goldberg AD, Stahl M, Famulare C, Tallman MS, Wang ES, Kuykendall AT, Rampal RK. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am J Hematol. 2022 Jan 1;97(1):E7-E10. doi: 10.1002/ajh.26381. Epub 2021 Oct 29. PMID: 34674293.

Li B, An W, Wang H, Baslan T, Mowla S, Krishnan A, Xiao W, Koche RP, Liu Y, Cai SF, Xiao Z, Derkach A, Iacobucci I, Mullighan CG, Helin K, Lowe SW, Levine RL, Rampal RK. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood. 2022 Jun 23;139(25):3630-3646. doi: 10.1182/blood.2021014465. PMID: 35421216; PMCID: PMC9728578.

Lu M, Xia L, Elmansy N, Clementelli C, Tremblay D, Hoffman R. Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells. Leukemia. 2022 Mar;36(3):733-745. doi: 10.1038/s41375-021-01446-4. Epub 2021 Oct 12. PMID: 34642468; PMCID: PMC8885407.

Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. PMID: 35007321; PMCID: PMC9101248.

Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA; Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematol. 2022 Jan;9(1):e38-e48. doi: 10.1016/S2352-3026(21)00343-4. PMID: 34971581; PMCID: PMC9098160.

Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, Gossett J, Marinaccio C, Weinberg R, Hoffman R, Migliaccio AR, Zheng Y, Derecka M, Rinaldi CR, Crispino JD. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022 Dec 29;140(26):2805-2817. doi: 10.1182/blood.2022017326. PMID: 36283106; PMCID: PMC9813832.

Migliaccio AR, Balduini A, Zhan H. Editorial: Megakaryocytes as regulators of tumor microenvironments. Front Oncol. 2022 Nov 25;12:1090658. doi: 10.3389/fonc.2022.1090658. PMID: 36505825; PMCID: PMC9732936.

Saleiro D, Wen JQ, Kosciuczuk EM, Eckerdt F, Beauchamp EM, Oku CV, Blyth GT, Fischietti M, Ilut L, Colamonici M, Palivos W, Atsaves PA, Tan D, Kocherginsky M, Weinberg RS, Fish EN, Crispino JD, Hoffman R, Platanias LC. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nat Commun. 2022 Apr 1;13(1):1750. doi: 10.1038/s41467-022-29381-7. PMID: 35365653; PMCID: PMC8975834.

Verachi P, Gobbo F, Martelli F, Martinelli A, Sarli G, Dunbar A, Levine RL, Hoffman R, Massucci MT, Brandolini L, Giorgio C, Allegretti M, Migliaccio AR. The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice. Front Oncol. 2022 Mar 22;12:853484. doi: 10.3389/fonc.2022.853484. PMID: 35392239; PMCID: PMC8982152.

Wang X, Rampal RK, Hu CS, Tripodi J, Farnoud N, Petersen B, Rossi MR, Patel M, McGovern E, Najfeld V, Iancu-Rubin C, Lu M, Davis A, Kremyanskaya M, Weinberg RS, Mascarenhas J, Hoffman R. Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase. JCI Insight. 2022 Apr 22;7(8):e156534. doi: 10.1172/jci.insight.156534. PMID: 35259128; PMCID: PMC9089790.

You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. PMID: 34699595; PMCID: PMC8854684.

Zingariello M, Verachi P, Gobbo F, Martelli F, Falchi M, Mazzarini M, Valeri M, Sarli G, Marinaccio C, Melo-Cardenas J, Crispino JD, Migliaccio AR. Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Gata1low Mice. Biomolecules. 2022 Jan 30;12(2):234. doi: 10.3390/biom12020234. PMID: 35204735; PMCID: PMC8961549.

2021

Brkic S, Stivala S, Santopolo A, Szybinski J, Jungius S, Passweg JR, Tsakiris D, Dirnhofer S, Hutter G, Leonards K, Lischer HEL, Dettmer MS, Neel BG, Levine RL, Meyer SC. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia. 2021 Oct;35(10):2875-2884. doi: 10.1038/s41375-021-01391-2. Epub 2021 Sep 3. PMID: 34480104; PMCID: PMC8478661.

Dunbar A, Park Y, Levine R. Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 Apr;35(2):237-251. doi: 10.1016/j.hoc.2021.01.001. Epub 2021 Feb 5. PMID: 33641866; PMCID: PMC7927771.

Farina M, Bernardi S, Polverelli N, D'Adda M, Malagola M, Bosio K, Re F, Almici C, Dunbar A, Levine RL, Russo D. Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells. 2021 Oct 15;10(10):2764. doi: 10.3390/cells10102764. PMID: 34685741; PMCID: PMC8534986.

Farina M, Russo D, Hoffman R. The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica. 2021 Nov 1;106(11):2813-2823. doi: 10.3324/haematol.2021.278499. PMID: 34320782; PMCID: PMC8561279.

Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas DG, Hajebrahimi MA, Pircher J, Silvestre-Roig C, Kotini AG, Luchsinger LL, Wei Y, Westerterp M, Snoeck HW, Papapetrou EP, Schulz C, Massberg S, Soehnlein O, Ebert B, Levine RL, Reilly MP, Libby P, Wang N, Tall AR. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021 Apr;592(7853):296-301. doi: 10.1038/s41586-021-03341-5. Epub 2021 Mar 17. PMID: 33731931; PMCID: PMC8038646.

Kosiorek HE, Dueck AC. Advancing Effective Clinical Trial Designs for Myelofibrosis. Hematol Oncol Clin North Am. 2021 Apr;35(2):431-444. doi: 10.1016/j.hoc.2020.12.009. PMID: 33641878; PMCID: PMC8687046.

Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting M, Jain J, Bennett CM, Resar LMS, Mascarenhas J, Verstovsek S, Hoffman R. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021 Mar;68(3):e28888. doi: 10.1002/pbc.28888. Epub 2020 Dec 31. PMID: 33381905; PMCID: PMC9040312.

Langlais BT, Mazza GL, Kosiorek HE, Palmer J, Mesa R, Dueck AC. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. J Hematol. 2021 Oct;10(5):207-211. doi: 10.14740/jh914. Epub 2021 Oct 31. PMID: 34804309; PMCID: PMC8577588.

Lonetti A, Indio V, Dianzani I, Ramenghi U, Da Costa L, Pospíšilová D, Migliaccio AR. The Glucocorticoid Receptor Polymorphism Landscape in Patients With Diamond Blackfan Anemia Reveals an Association Between Two Clinically Relevant Single Nucleotide Polymorphisms and Time to Diagnosis. Front Physiol. 2021 Oct 13;12:745032. doi: 10.3389/fphys.2021.745032. PMID: 34721069; PMCID: PMC8549833.

Marcellino BK, Hoffman R. Recent advances in prognostication and treatment of polycythemia vera. Fac Rev. 2021 Mar 12;10:29. doi: 10.12703/r/10-29. PMID: 33817698; PMCID: PMC8009192.

Marinaccio C, Suraneni P, Celik H, Volk A, Wen QJ, Ling T, Bulic M, Lasho T, Koche RP, Famulare CA, Farnoud N, Stein B, Schieber M, Gurbuxani S, Root DE, Younger ST, Hoffman R, Gangat N, Ntziachristos P, Chandel NS, Levine RL, Rampal RK, Challen GA, Tefferi A, Crispino JD. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 Jun;11(6):1398-1410. doi: 10.1158/2159-8290.CD-20-1353. Epub 2021 Feb 12. PMID: 33579786; PMCID: PMC8178182.

Martelli F, Verachi P, Zingariello M, Mazzarini M, Vannucchi AM, Lonetti A, Bacci B, Sarli G, Migliaccio AR. hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1low Mutation in Mice. Front Genet. 2021 Oct 11;12:720552. doi: 10.3389/fgene.2021.720552. PMID: 34707640; PMCID: PMC8542976.

Mazzarini M, Falchi M, Bani D, Migliaccio AR. Evolution and new frontiers of histology in bio-medical research. Microsc Res Tech. 2021 Feb;84(2):217-237. doi: 10.1002/jemt.23579. Epub 2020 Sep 11. PMID: 32915487; PMCID: PMC8103384.

Mazzarini M, Verachi P, Martelli F, Migliaccio AR. Role of β1 integrin in thrombocytopoiesis. Fac Rev. 2021 Sep 1;10:68. doi: 10.12703/r/10-68. PMID: 34557872; PMCID: PMC8442001.

Melo-Cardenas J, Migliaccio AR, Crispino JD. The Role of Megakaryocytes in Myelofibrosis. Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203. doi: 10.1016/j.hoc.2020.11.004. Epub 2021 Jan 11. PMID: 33641863; PMCID: PMC7921544.

Migliaccio AR. A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis. Cells. 2021 Nov 25;10(12):3302. doi: 10.3390/cells10123302. PMID: 34943811; PMCID: PMC8699046.

Migliaccio AR, Hoffman R. An Outline of the Outset of Thrombopoiesis in Human Embryos At Last. Cell Stem Cell. 2021 Mar 4;28(3):363-365. doi: 10.1016/j.stem.2021.02.007. PMID: 33667354; PMCID: PMC10450206.

Moliterno AR, Ginzburg YZ, Hoffman R. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043. PMID: 33237986; PMCID: PMC8215376.

Rampal RK, Pinzon-Ortiz M, Somasundara AVH, Durham B, Koche R, Spitzer B, Mowla S, Krishnan A, Li B, An W, Derkach A, Devlin S, Rong X, Longmire T, Eisman SE, Cordner K, Whitfield JT, Vanasse G, Cao ZA, Levine RL. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clin Cancer Res. 2021 Jun 15;27(12):3456-3468. doi: 10.1158/1078-0432.CCR-20-4898. Epub 2021 Mar 29. PMID: 33782031; PMCID: PMC8197756.

Stonestrom AJ, Levine RL. The BAFfling story of MN1-induced leukemogenesis. Mol Cell. 2021 Jun 3;81(11):2268-2269. doi: 10.1016/j.molcel.2021.05.001. PMID: 34087176; PMCID: PMC9278559.

Tremblay D, Mascarenhas J. Next Generation Therapeutics for the Treatment of Myelofibrosis. Cells. 2021 Apr 27;10(5):1034. doi: 10.3390/cells10051034. PMID: 33925695; PMCID: PMC8146033.

Tremblay D, Yacoub A, Hoffman R. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications. Hematol Oncol Clin North Am. 2021 Apr;35(2):159-176. doi: 10.1016/j.hoc.2020.12.001. Epub 2021 Jan 26. PMID: 33641861; PMCID: PMC8669599.

Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O'Connor-McCourt M, Migliaccio AR, Hoffman R. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight. 2021 Sep 22;6(18):e145651. doi: 10.1172/jci.insight.145651. PMID: 34383713; PMCID: PMC8492354.

Wang X, Hoffman R. What are the molecular mechanisms driving the switch from MPNs to leukemia? Best Pract Res Clin Haematol. 2021 Mar;34(1):101254. doi: 10.1016/j.beha.2021.101254. Epub 2021 Feb 8. PMID: 33762108; PMCID: PMC8686577.

Zhou S, Tremblay D, Hoffman R, Kremyanskaya M, Najfeld V, Li L, Moshier E, Mascarenhas J. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. Acta Haematol. 2021;144(1):48-57. doi: 10.1159/000506146. Epub 2020 Mar 11. PMID: 32160610; PMCID: PMC7773003.

2020

Bar-Natan M, Hoffman R. Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms. Expert Rev Hematol. 2020 Nov;13(11):1253-1264. doi: 10.1080/17474086.2020.1831381. Epub 2020 Oct 19. PMID: 33012187; PMCID: PMC8691658.

Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, Chen CW, Zou L, Cordner KB, DelGaudio NL, Durani V, Kini M, Rex M, Tian HS, Zuber J, Baslan T, Lowe SW, Rienhoff HY Jr, Letai A, Levine RL, Armstrong SA. Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer Discov. 2020 Oct;10(10):1500-1513. doi: 10.1158/2159-8290.CD-19-1469. Epub 2020 Jun 30. PMID: 32606137; PMCID: PMC7584353.

Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020 Jul 2;136(1):61-70. doi: 10.1182/blood.2019000943. PMID: 32430500; PMCID: PMC7332899.

Marcellino BK, Farnoud N, Cassinat B, Lu M, Verger E, McGovern E, Patel M, Medina-Martinez J, Levine MF, Arango Ossa JE, Zhou Y, Kosiorek H, Mehrotra M, Houldsworth J, Dueck A, Rossi M, Mascarenhas J, Kiladjian JJ, Rampal RK, Hoffman R. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Adv. 2020 Nov 24;4(22):5735-5744. doi: 10.1182/bloodadvances.2020002379. PMID: 33216890; PMCID: PMC7686898.

Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, Gerds A, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Farnoud N, Krishnan A, Weinberg RS, McGovern E, Salama ME, Najfeld V, Medina-Martinez JS, Arango Ossa JE, Levine MF, Zhou Y, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020 Oct 27;4(20):5246-5256. doi: 10.1182/bloodadvances.2020002119. PMID: 33104796; PMCID: PMC7594401.

Migliaccio AR. GATA1 gets personal. Haematologica. 2020 Apr;105(4):852-854. doi: 10.3324/haematol.2019.246355. PMID: 32238463; PMCID: PMC7109728.

Morinishi L, Kochanowski K, Levine RL, Wu LF, Altschuler SJ. Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions. Cell Syst. 2020 Jul 22;11(1):86-94.e5. doi: 10.1016/j.cels.2020.06.003. Epub 2020 Jul 2. PMID: 32619551; PMCID: PMC7428059.

Pastore F, Krishnan A, Hammarén HM, Silvennoinen O, Yan B, Levine RL. JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs. Blood Adv. 2020 Sep 22;4(18):4554-4559. doi: 10.1182/bloodadvances.2019001283. PMID: 32956452; PMCID: PMC7509885.

Pastore F, Bhagwat N, Pastore A, Radzisheuskaya A, Karzai A, Krishnan A, Li B, Bowman RL, Xiao W, Viny AD, Zouak A, Park YC, Cordner KB, Braunstein S, Maag JL, Grego A, Mehta J, Wang M, Lin H, Durham BH, Koche RP, Rampal RK, Helin K, Scherle P, Vaddi K, Levine RL. PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. Cancer Discov. 2020 Nov;10(11):1742-1757. doi: 10.1158/2159-8290.CD-20-0026. Epub 2020 Jul 15. PMID: 32669286; PMCID: PMC7642059.

Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O'Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L, Chiaramonte M, Salehi M, Ziadkhanpour K, Nguyen H, Siwoski O, Hung AK, Janania Martinez M, Nguyen J, Patel S, Kollipara R, Dave A, Randall M, Grant M, Harrison M, Fernandez Soto P, Tremblay D, Hoffman R, Moshier E, Mascarenhas J. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 May 7;135(19):1696-1703. doi: 10.1182/blood.2019003347. PMID: 32107559; PMCID: PMC7205813.

Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A, Kremyanskaya M, Hoffman R, Mauro MJ, Rampal RK, Mascarenhas J. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2020 Mar;61(3):660-667. doi: 10.1080/10428194.2019.1688323. Epub 2019 Nov 12. PMID: 31711337; PMCID: PMC7771191.

Tremblay D, Schwartz M, Bakst R, Patel R, Schiano T, Kremyanskaya M, Hoffman R, Mascarenhas J. Modern management of splenomegaly in patients with myelofibrosis. Ann Hematol. 2020 Jul;99(7):1441-1451. doi: 10.1007/s00277-020-04069-4. Epub 2020 May 17. PMID: 32417942; PMCID: PMC7809704.

Tremblay D, Vogel AS, Moshier E, Hoffman R, Kremyanskaya M, Zhou S, Schiano T, Mascarenhas J. Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience. Eur J Haematol. 2020 Jan;104(1):72-73. doi: 10.1111/ejh.13335. Epub 2019 Oct 16. PMID: 31587352; PMCID: PMC7781435.

Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington JMR, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther GW, Wright KL, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood. 2020 Jan 16;135(3):191-207. doi: 10.1182/blood.2019895326. PMID: 31750881; PMCID: PMC6966930.

Zhang X, Song J, Shah BN, Nekhai S, Miasnikova G, Sergueeva A, Prchal JT, Gordeuk VR. Peripheral blood mononuclear cells show prominent gene expression by erythroid progenitors in diseases characterized by heightened erythropoiesis. Br J Haematol. 2020 Jul;190(1):e42-e45. doi: 10.1111/bjh.16696. Epub 2020 May 12. PMID: 32399971; PMCID: PMC7798416.

Zingariello M, Martelli F, Verachi P, Bardelli C, Gobbo F, Mazzarini M, Migliaccio AR. Novel targets to cure primary myelofibrosis from studies on Gata1low mice. IUBMB Life. 2020 Jan;72(1):131-141. doi: 10.1002/iub.2198. Epub 2019 Nov 21. PMID: 31749302; PMCID: PMC7256843.

Zingariello M, Rosti V, Vannucchi AM, Guglielmelli P, Mazzarini M, Barosi G, Genova ML, Migliaccio AR. Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. Front Oncol. 2020 Nov 16;10:584541. doi: 10.3389/fonc.2020.584541. PMID: 33312951; PMCID: PMC7701330.

2019

Cimen Bozkus C, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, Bhardwaj N. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discov. 2019 Sep;9(9):1192-1207. doi: 10.1158/2159-8290.CD-18-1356. Epub 2019 Jul 2. PMID: 31266769; PMCID: PMC6726533.

Eran Z, Zingariello M, Bochicchio MT, Bardelli C, Migliaccio AR. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. F1000Res. 2019 Sep 19;8:F1000 Faculty Rev-1662. doi: 10.12688/f1000research.18581.1. PMID: 31583083; PMCID: PMC6758840.

Federici G, Varricchio L, Martelli F, Falchi M, Picconi O, Francescangeli F, Contavalli P, Girelli G, Tafuri A, Petricoin EF 3rd, Mazzarini M, Zeuner A, Migliaccio AR. Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. Front Oncol. 2019 Nov 22;9:1245. doi: 10.3389/fonc.2019.01245. PMID: 31824842; PMCID: PMC6883719.

Gangaraju R, Carroll AJ, Prchal JT. Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26). Ann Hematol. 2019 Nov 1. doi: 10.1007/s00277-019-03805-9. Epub ahead of print. PMID: 31676985.

Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant. 2019 Feb;25(2):256-264. doi: 10.1016/j.bbmt.2018.09.001. Epub 2018 Sep 8. PMID: 30205231; PMCID: PMC6339828.

Ishikawa G, Fujiwara N, Hirschfield H, Varricchio L, Hoshida Y, Barosi G, Rosti V, Padilla M, Mazzarini M, Friedman SL, Hoffman R, Migliaccio AR. Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Exp Hematol. 2019 Nov;79:16-25.e3. doi: 10.1016/j.exphem.2019.10.001. Epub 2019 Nov 1. PMID: 31678370; PMCID: PMC6910948.

Mascarenhas J, Baer MR, Kessler C, Hexner E, Tremblay D, Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, Hoffman R. Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. PMID: 30668266; PMCID: PMC6530779.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. PMID: 31363161; PMCID: PMC6884668.

Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R. Oral idasanutlin in patients with polycythemia vera. Blood. 2019 Aug 8;134(6):525-533. doi: 10.1182/blood.2018893545. Epub 2019 Jun 5. PMID: 31167802; PMCID: PMC6688433.

Merlinsky TR, Levine RL, Pronier E. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis. Clin Cancer Res. 2019 May 15;25(10):2956-2962. doi: 10.1158/1078-0432.CCR-18-3777. Epub 2019 Jan 17. PMID: 30655313; PMCID: PMC6522317.

Migliaccio AR. GATA1 gets personal. Haematologica. 2020 Apr;105(4):852-854. doi: 10.3324/haematol.2019.246355. PMID: 32238463; PMCID: PMC7109728.

Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019 Jul;571(7765):355-360. doi: 10.1038/s41586-019-1367-0. Epub 2019 Jul 3. PMID: 31270458; PMCID: PMC6782071.

Sapre M, Tremblay D, Wilck E, James A, Leiter A, Coltoff A, Koshy AG, Kremyanskaya M, Hoffman R, Mascarenhas JO, Gallagher EJ. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Sci Rep. 2019 Nov 12;9(1):16609. doi: 10.1038/s41598-019-53056-x. PMID: 31719581; PMCID: PMC6851362.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. PMID: 30730307; PMCID: PMC6436863.

Takashima S, Martin ML, Jansen SA, Fu Y, Bos J, Chandra D, O'Connor MH, Mertelsmann AM, Vinci P, Kuttiyara J, Devlin SM, Middendorp S, Calafiore M, Egorova A, Kleppe M, Lo Y, Shroyer NF, Cheng EH, Levine RL, Liu C, Kolesnick R, Lindemans CA, Hanash AM. T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage. Sci Immunol. 2019 Dec 6;4(42):eaay8556. doi: 10.1126/sciimmunol.aay8556. PMID: 31811055; PMCID: PMC7239329.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6. PMID: 30625392; PMCID: PMC6918823.

Woods B, Chen W, Chiu S, Marinaccio C, Fu C, Gu L, Bulic M, Yang Q, Zouak A, Jia S, Suraneni PK, Xu K, Levine RL, Crispino JD, Wen QJ. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo. Clin Cancer Res. 2019 Oct 1;25(19):5901-5912. doi: 10.1158/1078-0432.CCR-18-4089. Epub 2019 Jun 19. PMID: 31217200; PMCID: PMC6774846.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. PMID: 31515250; PMCID: PMC6839950.

2018

Gnanapragasam MN, Crispino JD, Ali AM, Weinberg R, Hoffman R, Raza A, Bieker JJ. Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep. 2018 Apr 26;8(1):6587. doi: 10.1038/s41598-018-24962-3. PMID: 29700354; PMCID: PMC5920080.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024. Erratum for: Cancer Cell. 2018 Jan 8;33(1):29-43.e7. doi: 10.1016/j.ccell.2017.11.009. PMID: 29634952; PMCID: PMC5908465.

Ling T, Crispino JD, Zingariello M, Martelli F, Migliaccio AR. GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol. 2018 Mar;11(3):169-184. doi: 10.1080/17474086.2018.1436965. Epub 2018 Feb 19. PMID: 29400094; PMCID: PMC6108178.

Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, Rampal RK, Dueck A, Najfeld V. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018 Dec 26;2(24):3581-3589. doi: 10.1182/bloodadvances.2018024018. PMID:

Migliaccio AR. A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol. 2018 Mar;59:9-13. doi: 10.1016/j.exphem.2017.12.004. Epub 2017 Dec 15. PMID: 29248611; PMCID: PMC6381597.

Migliaccio AR, Uversky VN. Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulum. J Biomol Struct Dyn. 2018 May;36(6):1617-1636. doi: 10.1080/07391102.2017.1330224. Epub 2017 May 26. PMID: 28504081; PMCID: PMC6243143.

Migliaccio AR, Varricchio L. Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells. 2018 Feb;36(2):172-179. doi: 10.1002/stem.2735. Epub 2017 Dec 5. PMID: 29124822; PMCID: PMC5785423.

Peeken JC, Jutzi JS, Wehrle J, Koellerer C, Staehle HF, Becker H, Schoenwandt E, Seeger TS, Schanne DH, Gothwal M, Ott CJ, Gründer A, Pahl HL. Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood. 2018 May 3;131(18):2065-2073. doi: 10.1182/blood-2017-10-810622. Epub 2018 Mar 8. PMID: 29519804; PMCID: PMC5934799.

Pronier E, Cifani P, Merlinsky TR, Berman KB, Somasundara AVH, Rampal RK, LaCava J, Wei KE, Pastore F, Maag JL, Park J, Koche R, Kentsis A, Levine RL. Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight. 2018 Nov 15;3(22):e122703. doi: 10.1172/jci.insight.122703. PMID: 30429377; PMCID: PMC6302938.

Qiu J, Salama ME, Hu CS, Li Y, Wang X, Hoffman R. The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv. 2018 May 22;2(10):1130-1145. doi: 10.1182/bloodadvances.2017015073. PMID: 29776986; PMCID: PMC5965045.

Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661. PMID: 30563881; PMCID: PMC6306885.

Wang X, Hu CS, Petersen B, Qiu J, Ye F, Houldsworth J, Eng K, Huang F, Hoffman R. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018 Sep 25;2(18):2378-2388. doi: 10.1182/bloodadvances.2018022012. PMID: 30242099; PMCID: PMC6156882.

Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M. Novel treatments to tackle myelofibrosis. Expert Rev Hematol. 2018 Nov;11(11):889-902. doi: 10.1080/17474086.2018.1536538. Epub 2018 Oct 26. PMID: 30324817.

Zimran E, Tripodi J, Rampal R, Rappoport F, Zirkiev S, Hoffman R, Najfeld V. Genomic characterization of spleens in patients with myelofibrosis. Haematologica. 2018 Oct;103(10):e446-e449. doi: 10.3324/haematol.2018.193763. Epub 2018 May 10. PMID: 29748436; PMCID: PMC6165826.

2017

Falchi M, Varricchio L, Martelli F, Marra M, Picconi O, Tafuri A, Girelli G, Uversky VN, Migliaccio AR. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp Hematol. 2017 Jun;50:53-76. doi: 10.1016/j.exphem.2017.02.001. Epub 2017 Feb 21. PMID: 28232234; PMCID: PMC5779852.

Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 3;127(4):1316-1320. doi: 10.1172/JCI82905. Epub 2017 Feb 27. PMID: 28240607; PMCID: PMC5373858.

Lanikova L, Reading NS, Hu H, Tashi T, Burjanivova T, Shestakova A, Siwakoti B, Thakur BK, Pun CB, Sapkota A, Abdelaziz S, Feng BJ, Huff CD, Hashibe M, Prchal JT. Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget. 2017 Feb 14;8(7):11739-11747. doi: 10.18632/oncotarget.14340. PMID: 28036300; PMCID: PMC5355300.

Sergueeva A, Miasnikova G, Shah BN, Song J, Lisina E, Okhotin DJ, Nouraie M, Nekhai S, Ammosova T, Niu XM, Prchal JT, Zhang X, Gordeuk VR. Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica. 2017 May;102(5):e166-e169. doi: 10.3324/haematol.2016.158170. Epub 2017 Jan 19. PMID: 28104701; PMCID: PMC5477617.

Tashi T, Scott Reading N, Wuren T, Zhang X, Moore LG, Hu H, Tang F, Shestakova A, Lorenzo F, Burjanivova T, Koul P, Guchhait P, Wittwer CT, Julian CG, Shah B, Huff CD, Gordeuk VR, Prchal JT, Ge R. Gain-of-function EGLN1 prolyl hydroxylase (PHD2 D4E:C127S) in combination with EPAS1 (HIF-2α) polymorphism lowers hemoglobin concentration in Tibetan highlanders. J Mol Med (Berl). 2017 Jun;95(6):665-670. doi: 10.1007/s00109-017-1519-3. Epub 2017 Feb 23. PMID: 28233034.

Varricchio L, Falchi M, Dall'Ora M, De Benedittis C, Ruggeri A, Uversky VN, Migliaccio AR. Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function. Front Cell Dev Biol. 2017 Nov 23;5:96. doi: 10.3389/fcell.2017.00096. PMID: 29218307; PMCID: PMC5703715.

Zingariello M, Sancillo L, Martelli F, Ciaffoni F, Marra M, Varricchio L, Rana RA, Zhao C, Crispino JD, Migliaccio AR. The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J. 2017 Jun 16;7(6):e572. doi: 10.1038/bcj.2017.51. PMID: 28622305; PMCID: PMC5520398.

2016

Aruch D, Schwartz M, Mascarenhas J, Kremyanskaya M, Newsom C, Hoffman R. Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):e133-e137. doi: 10.1016/j.clml.2016.06.007. Epub 2016 Jun 8. PMID: 27373368.

Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF 3rd, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR. Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. Exp Hematol. 2016 Dec;44(12):1138-1155.e4. doi: 10.1016/j.exphem.2016.08.007. Epub 2016 Aug 31. PMID: 27592389; PMCID: PMC5778911.

Divoky V, Song J, Horvathova M, Kralova B, Votavova H, Prchal JT, Yoon D. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl). 2016 May;94(5):597-608. doi: 10.1007/s00109-015-1375-y. Epub 2015 Dec 26. PMID: 26706855; PMCID: PMC5083035.

Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, Najfeld V, Kremyanskaya M, Isola L, Hoffman R, Mascarenhas J. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biol Blood Marrow Transplant. 2016 Dec;22(12):2180-2186. doi: 10.1016/j.bbmt.2016.08.029. Epub 2016 Sep 3. PMID: 27596130..

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, […], Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. Erratum in: Autophagy. 2016;12(2):443. doi: 10.1080/15548627.2016.1147886. Selliez, Iban [corrected to Seiliez, Iban]. PMID: 26799652; PMCID: PMC4835977.

Kovacsovics-Bankowski M, Kelley TW, Efimova O, Kim SJ, Wilson A, Swierczek S, Prchal J. Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol. 2016 Sep 27;5:28. doi: 10.1186/s40164-016-0057-y. PMID: 27708986; PMCID: PMC5037882.

Lanikova L, Babosova O, Swierczek S, Wang L, Wheeler DA, Divoky V, Korinek V, Prchal JT. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera. Blood. 2016 Nov 3;128(18):2266-2270. doi: 10.1182/blood-2016-04-711283. Epub 2016 Sep 19. PMID: 27647865; PMCID: PMC5095759.

Mascarenhas J. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S124-9. doi: 10.1016/j.clml.2016.02.016. PMID: 27521308.

Migliaccio AR. To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol. 2016 Aug;44(8):706-12. doi: 10.1016/j.exphem.2016.04.016. Epub 2016 May 6. PMID: 27157594; PMCID: PMC5778909.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19. PMID: 26493563; PMCID: PMC5030817.

Spangrude GJ, Lewandowski D, Martelli F, Marra M, Zingariello M, Sancillo L, Rana RA, Migliaccio AR. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells. 2016 Jan;34(1):67-82. doi: 10.1002/stem.2229. Epub 2015 Oct 23. PMID: 26439305.

Wang L, Wheeler DA, Prchal JT. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol. 2016 Aug;44(8):644-52. doi: 10.1016/j.exphem.2015.11.005. Epub 2015 Dec 2. PMID: 26646991; PMCID: PMC5268131.

Wang X, Haylock D, Hu CS, Kowalczyk W, Jiang T, Qiu J, Mosoyan G, He W, Marshall N, Mascarenhas J, Tarasova A, Brody J, Winkler D, Hoffman R. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. 2016 Jun 30;127(26):3398-409. doi: 10.1182/blood-2015-10-674465. Epub 2016 Apr 25. Erratum in: Blood. 2017 Dec 21;130(25):2809. doi: 10.1182/blood-2017-11-815340. PMID: 27114459; PMCID: PMC4929928.

Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283. PMID: 27252511; PMCID: PMC5013940.

2015

Ciaffoni F, Cassella E, Varricchio L, Massa M, Barosi G, Migliaccio AR. Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells Mol Dis. 2015 Mar;54(3):234-41. doi: 10.1016/j.bcmd.2014.12.005. Epub 2015 Jan 15. PMID: 25703685; PMCID: PMC4338409.

Falchi M, Varricchio L, Martelli F, Masiello F, Federici G, Zingariello M, Girelli G, Whitsett C, Petricoin EF 3rd, Moestrup SK, Zeuner A, Migliaccio AR. Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. Haematologica. 2015 Feb;100(2):178-87. doi: 10.3324/haematol.2014.114405. Epub 2014 Dec 22. PMID: 25533803; PMCID: PMC4803138.

Funnell AP, Prontera P, Ottaviani V, Piccione M, Giambona A, Maggio A, Ciaffoni F, Stehling-Sun S, Marra M, Masiello F, Varricchio L, Stamatoyannopoulos JA, Migliaccio AR, Papayannopoulou T. 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood. 2015 Jul 2;126(1):89-93. doi: 10.1182/blood-2015-04-638528. Epub 2015 May 27. PMID: 26019277; PMCID: PMC4492199.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis. 2015 Feb 9;4(2):e137. doi: 10.1038/oncsis.2014.51. PMID: 25664930; PMCID: PMC4338425.

Heideveld E, Masiello F, Marra M, Esteghamat F, Yağcı N, von Lindern M, Migliaccio AR, van den Akker E. CD14+ cells from peripheral blood positively regulate hematopoietic stem and progenitor cell survival resulting in increased erythroid yield. Haematologica. 2015 Nov;100(11):1396-406. doi: 10.3324/haematol.2015.125492. Epub 2015 Aug 20. PMID: 26294724; PMCID: PMC4825294.

Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20. PMID: 25563429; PMCID: PMC5665563.

Iancu-Rubin C, Hoffman R. Role of epigenetic reprogramming in hematopoietic stem cell function. Curr Opin Hematol. 2015 Jul;22(4):279-85. doi: 10.1097/MOH.0000000000000143. PMID: 26049747.

King KY, Matatall KA, Shen CC, Goodell MA, Swierczek SI, Prchal JT. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol. 2015 Oct;43(10):912-918.e2. doi: 10.1016/j.exphem.2015.05.013. Epub 2015 Jun 11. PMID: 26072330; PMCID: PMC4592796.

Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, Lew J, Weinberg R, Goldberg JD, Hoffman R. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. 2015 Aug 20;126(8):972-82. doi: 10.1182/blood-2014-12-618595. Epub 2015 May 28. PMID: 26022238; PMCID: PMC4543230.

Mascarenhas J. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2015;2015:329-39. doi: 10.1182/asheducation-2015.1.329. PMID: 26637740.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006. PMID: 26175413; PMCID: PMC4503933.

Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2015 Jul;56(7):1938-48. doi: 10.3109/10428194.2014.974594. Epub 2014 Nov 19. PMID: 25330439; PMCID: PMC5076856.

Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol. 2015 Jul;43(7):537-45.e1-11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24. PMID: 25912019; PMCID: PMC4487517.

Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol. 2015 Nov 20;33(33):3953-60. doi: 10.1200/JCO.2015.61.6474. Epub 2015 Aug 31. PMID: 26324368; PMCID: PMC4979103.

Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia. 2015 Dec;29(12):2432-4. doi: 10.1038/leu.2015.249. Epub 2015 Sep 15. PMID: 26369983; PMCID: PMC5083033.

Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015 May;50(5):628-36. doi: 10.1038/bmt.2014.323. Epub 2015 Feb 9. PMID: 25665047; PMCID: PMC6394215.

Wang X, Cho SY, Hu CS, Chen D, Roboz J, Hoffman R. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol. 2015 Feb;43(2):100-9.e1. doi: 10.1016/j.exphem.2014.10.013. Epub 2014 Nov 8. PMID: 25461253; PMCID: PMC4324010.

Zingariello M, Ruggeri A, Martelli F, Marra M, Sancillo L, Ceglia I, Rana RA, Migliaccio AR. A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis. Am J Blood Res. 2015 Dec 25;5(2):34-61. PMID: 27069753; PMCID: PMC4769347.

2014

Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hämäläinen S, Seppänen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreðsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014 Feb 6;123(6):863-74. doi: 10.1182/blood-2013-07-517151. Epub 2013 Dec 17. PMID: 24345756; PMCID: PMC3916878.

Essig A, Duque-Afonso J, Schwemmers S, Pahl HL, Lübbert M. The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk Res. 2014 Mar;38(3):340-5. doi: 10.1016/j.leukres.2013.12.014. Epub 2013 Dec 25. PMID: 24456692; PMCID: PMC4135084.

Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, Prchal JT. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood. 2014 Jan 16;123(3):391-4. doi: 10.1182/blood-2013-10-534222. Epub 2013 Dec 2. PMID: 24297870; PMCID: PMC3952363..

Lindner SE, Wissler M, Gründer A, Aumann K, Ottina E, Peintner L, Brauns-Schubert P, Preiss F, Herzog S, Borner C, Charvet C, Villunger A, Pahl HL, Maurer U. Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation. Oncogene. 2014 Oct 30;33(44):5221-4. doi: 10.1038/onc.2013.469. Epub 2013 Nov 11. PMID: 24213575; PMCID: PMC4155018.

Lorenzo FR, Huff C, Myllymäki M, Olenchock B, Swierczek S, Tashi T, Gordeuk V, Wuren T, Ri-Li G, McClain DA, Khan TM, Koul PA, Guchhait P, Salama ME, Xing J, Semenza GL, Liberzon E, Wilson A, Simonson TS, Jorde LB, Kaelin WG Jr, Koivunen P, Prchal JT. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet. 2014 Sep;46(9):951-6. doi: 10.1038/ng.3067. Epub 2014 Aug 17. PMID: 25129147; PMCID: PMC4473257.

Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014 Jul 31;124(5):771-9. doi: 10.1182/blood-2013-11-536854. Epub 2014 May 28. PMID: 24869939; PMCID: PMC4467881.

Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B, Falanga A. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol. 2014 Jan;89(1):68-73. doi: 10.1002/ajh.23590. Epub 2013 Nov 20. PMID: 24009132; PMCID: PMC3946818.

Mascarenhas J, Mesa R, Prchal J, Hoffman R. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica. 2014 Jun;99(6):945-9. doi: 10.3324/haematol.2014.106013. PMID: 24881037; PMCID: PMC4040888.

Paciaroni K, Lucarelli G, Martelli F, Migliaccio AR, von Lindern M, Borg J, Gillemans N, van Dijk TB, Philipsen S. Transfusion-independent β(0)-thalassemia after bone marrow transplantation failure: proposed involvement of high parental HbF and an epigenetic mechanism. Am J Blood Res. 2014 Sep 5;4(1):27-32. PMID: 25232502; PMCID: PMC4165118.

Rheinemann L, Seeger TS, Wehrle J, Pahl HL. NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway. Haematologica. 2014 Oct;99(10):e208-10. doi: 10.3324/haematol.2014.106393. Epub 2014 Jun 20. PMID: 24951464; PMCID: PMC4181273.

Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014 Aug 14;124(7):1183-91. doi: 10.1182/blood-2014-04-572545. Epub 2014 Jun 24. PMID: 24963042; PMCID: PMC4133490.

Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):663-8. doi: 10.1097/PAI.0000000000000000. PMID: 24897074; PMCID: PMC4394898.

Spivak JL. The polycythemia vera stem cell. Leuk Suppl. 2014 Dec;3(Suppl 1):S23-4. doi: 10.1038/leusup.2014.13. Epub 2014 Dec 17. PMID: 27175268; PMCID: PMC4851290.

Tashi T, Feng T, Koul P, Amaru R, Hussey D, Lorenzo FR, RiLi G, Prchal JT. High altitude genetic adaptation in Tibetans: no role of increased hemoglobin-oxygen affinity. Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):27-9. doi: 10.1016/j.bcmd.2014.02.003. Epub 2014 Mar 4. PMID: 24618341; PMCID: PMC4039493.

Varricchio L, Dell'Aversana C, Nebbioso A, Migliaccio G, Altucci L, Mai A, Grazzini G, Bieker JJ, Migliaccio AR. Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. Int J Biochem Cell Biol. 2014 May;50:112-22. doi: 10.1016/j.biocel.2014.02.019. Epub 2014 Mar 1. PMID: 24594363; PMCID: PMC4003889.

Varricchio L, Migliaccio AR. The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis. Am J Blood Res. 2014 Dec 15;4(2):53-72. PMID: 25755906; PMCID: PMC4348794.

Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia. 2014 Apr;28(4):935-8. doi: 10.1038/leu.2014.7. Epub 2014 Jan 13. PMID: 24413320; PMCID: PMC4532385.

Wang L, Swierczek SI, Lanikova L, Kim SJ, Hickman K, Walker K, Wang K, Drummond J, Doddapaneni H, Reid JG, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. Leukemia. 2014 Apr;28(4):938-41. doi: 10.1038/leu.2014.20. Epub 2014 Jan 27. PMID: 24463469; PMCID: PMC4532371.

Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014 Nov 6;124(19):2987-95. doi: 10.1182/blood-2014-02-558015. Epub 2014 Sep 5. PMID: 25193869; PMCID: PMC4224194.

Wehrle J, Pahl HL, von Bubnoff N. Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res. 2014;201:99-107. doi: 10.1007/978-3-642-54490-3_5. PMID: 24756787.

Ye Z, Liu CF, Lanikova L, Dowey SN, He C, Huang X, Brodsky RA, Spivak JL, Prchal JT, Cheng L. Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells. 2014 Jan;32(1):269-78. doi: 10.1002/stem.1545. PMID: 24105986; PMCID: PMC4096297.

Zetterberg E, Verrucci M, Martelli F, Zingariello M, Sancillo L, D'Amore E, Rana RA, Migliaccio AR. Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets. 2014;25(7):539-47. doi: 10.3109/09537104.2013.840720. Epub 2013 Oct 31. PMID: 24176039; PMCID: PMC4045657.

Zhang X, Zhang W, Ma SF, Desai AA, Saraf S, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Abbasi T, Casanova NG, Steinberg MH, Baldwin CT, Sebastiani P, Prchal JT, Kittles R, Garcia JG, Machado RF, Gordeuk VR. Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation. 2014 Apr 22;129(16):1650-8. doi: 10.1161/CIRCULATIONAHA.113.005296. Epub 2014 Feb 10. PMID: 24515990; PMCID: PMC4287376.

Zhang X, Zhang W, Ma SF, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Nourai M, Wade MS, Prchal JT, Garcia JGN, Machado RF, Gordeuk VR. Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. Blood Cells Mol Dis. 2014 Jan;52(1):35-45. doi: 10.1016/j.bcmd.2013.07.016. Epub 2013 Aug 28. PMID: 23993337; PMCID: PMC3852195.

2013

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood. 2013 Jul 4;122(1):93-9. doi: 10.1182/blood-2012-11-463257. Epub 2013 May 13. PMID: 23670178; PMCID: PMC3701907.

Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16. PMID: 23591792; PMCID: PMC3674675.

Bogeska R, Pahl HL. Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. Stem Cells Transl Med. 2013 Feb;2(2):112-7. doi: 10.5966/sctm.2012-0046. Epub 2013 Jan 22. PMID: 23341442; PMCID: PMC3659758..

Hricik T, Federici G, Zeuner A, Alimena G, Tafuri A, Tirelli V, Varricchio L, Masiello F, Ciaffoni F, Vaglio S, Petricoin EF, Girelli G, Levine RL, Migliaccio AR. Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. Am J Hematol. 2013 Sep;88(9):723-9. doi: 10.1002/ajh.23487. Epub 2013 Jul 3. PMID: 23720412; PMCID: PMC3771389.

Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Kamar Wang W, Döhner K, Jansen JH, Pahl HL. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med. 2013 May 6;210(5):1003-19. doi: 10.1084/jem.20120521. PMID: 23589569; PMCID: PMC3646501.

Labi V, Bertele D, Woess C, Tischner D, Bock FJ, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM, Villunger A, Erlacher M. Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. EMBO Mol Med. 2013 Jan;5(1):122-36. doi: 10.1002/emmm.201201235. Epub 2012 Nov 24. PMID: 23180554; PMCID: PMC3569658.

Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K, Prchal JT. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013 Apr;91(4):507-12. doi: 10.1007/s00109-012-0967-z. Epub 2012 Oct 23. PMID: 23090011; PMCID: PMC3570726.

Lorenzo FR, Yang C, Lanikova L, Butros L, Zhuang Z, Prchal JT. Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia. Br J Haematol. 2013 Sep;162(6):851-3. doi: 10.1111/bjh.12431. Epub 2013 Jun 17. PMID: 23772956; PMCID: PMC3759558.

McClain DA, Abuelgasim KA, Nouraie M, Salomon-Andonie J, Niu X, Miasnikova G, Polyakova LA, Sergueeva A, Okhotin DJ, Cherqaoui R, Okhotin D, Cox JE, Swierczek S, Song J, Simon MC, Huang J, Simcox JA, Yoon D, Prchal JT, Gordeuk VR. Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glucose metabolism. J Mol Med (Berl). 2013 Jan;91(1):59-67. doi: 10.1007/s00109-012-0961-5. Epub 2012 Sep 27. PMID: 23015148; PMCID: PMC3537876.

Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 2013 Sep;98(9):1421-3. doi: 10.3324/haematol.2012.083337. Epub 2013 Jun 28. PMID: 23812932; PMCID: PMC3762099.

Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J, Jarosova M, Urbankova H, Indrak K, Prchal JT, Divoky V. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 2013 Feb;88(2):157-8. doi: 10.1002/ajh.23362. Epub 2012 Dec 24. PMID: 23280542; PMCID: PMC3556177.

Szankasi P, Reading NS, Vaughn CP, Prchal JT, Bahler DW, Kelley TW. A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves. J Mol Diagn. 2013 Mar;15(2):248-54. doi: 10.1016/j.jmoldx.2012.11.005. Epub 2013 Jan 8. PMID: 23313362; PMCID: PMC5808148.

Tomasic NL, Piterkova L, Huff C, Bilic E, Yoon D, Miasnikova GY, Sergueeva AI, Niu X, Nekhai S, Gordeuk V, Prchal JT. The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W). Haematologica. 2013 Apr;98(4):560-7. doi: 10.3324/haematol.2012.070508. Epub 2013 Feb 12. PMID: 23403324; PMCID: PMC3659987.

Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica. 2013 Jul;98(7):1073-80. doi: 10.3324/haematol.2012.071183. Epub 2013 Feb 26. PMID: 23445878; PMCID: PMC3696611.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3. PMID: 22858987.

Zangari M, Fink L, Tolomelli G, Lee JC, Stein BL, Hickman K, Swierczek S, Kelley TW, Berno T, Moliterno AR, Spivak JL, Gordeuk VR, Prchal JT. Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera? Blood Coagul Fibrinolysis. 2013 Apr;24(3):311-6. doi: 10.1097/MBC.0b013e32835bfdb9. PMID: 23392352; PMCID: PMC3796441.

Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D'Amore E, Massa M, Barosi G, Sancillo L, Li X, Goldberg JD, Rana RA, Migliaccio AR. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013 Apr 25;121(17):3345-63. doi: 10.1182/blood-2012-06-439661. Epub 2013 Mar 5. PMID: 23462118; PMCID: PMC3637011.

2012

Barosi G. Emerging targeted therapies in myelofibrosis. Expert Rev Hematol. 2012 Jun;5(3):313-24. doi: 10.1586/ehm.12.17. PMID: 22780211.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L]. PMID: 23071245; PMCID: PMC4872304.

Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012 Jul;40(7):564-74. doi: 10.1016/j.exphem.2012.02.004. Epub 2012 Feb 27. PMID: 22381681; PMCID: PMC3381910.

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012 Jan 16;209(1):35-50. doi: 10.1084/jem.20110540. Epub 2012 Jan 9. PMID: 22231305; PMCID: PMC3260873.

Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL, van der Reijden BA, Jansen JH. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood. 2012 Feb 2;119(5):1318-9. doi: 10.1182/blood-2011-07-365213. PMID: 22308284.

Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, Kremyanskaya M, Najfeld V, Hoffman R. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012 Oct 11;120(15):3098-105. doi: 10.1182/blood-2012-02-410712. Epub 2012 Aug 7. PMID: 22872685; PMCID: PMC3471518.

Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R; Post-myeloproliferative neoplasm acute myeloid leukemia consortium. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012 Dec;36(12):1500-4. doi: 10.1016/j.leukres.2012.08.013. Epub 2012 Aug 28. PMID: 22938832; PMCID: PMC4114151.

Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012 Jun 1;18(11):3008-14. doi: 10.1158/1078-0432.CCR-11-3145. Epub 2012 Apr 2. PMID: 22474318.

Nussenzveig RH, Burjanivova T, Salama ME, Ogilvie NW, Marcinek J, Plank L, Agarwal AM, Perkins SL, Prchal JT. Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. Leuk Lymphoma. 2012 Dec;53(12):2479-86. doi: 10.3109/10428194.2012.697562. Epub 2012 Jul 9. PMID: 22642932.

Pahl HL. A JAK-in-the-cell cycle. Blood. 2012 Feb 2;119(5):1096-7. doi: 10.1182/blood-2011-11-393462. PMID: 22308276.

Poletto V, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R, Massa M, Martinetti M, Viarengo G, Malovini A, Migliaccio AR, Barosi G. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood. 2012 Oct 11;120(15):3112-7. doi: 10.1182/blood-2012-05-433466. Epub 2012 Aug 9. PMID: 22879541; PMCID: PMC3628115.

Prchal JT. Molecular basis of polycythemic disorders due to aberrant hypoxia sensing and its relevance to acute leukemia. Best Pract Res Clin Haematol. 2012 Dec;25(4):493-7. doi: 10.1016/j.beha.2012.10.014. Epub 2012 Oct 25. PMID: 23200548; PMCID: PMC3513693.

Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol. 2012 Jun;25(6):815-27. doi: 10.1038/modpathol.2012.33. Epub 2012 Mar 2. PMID: 22388763; PMCID: PMC3632395.

Rogers H, Wang L, Yu X, Alnaeeli M, Cui K, Zhao K, Bieker JJ, Prchal J, Huang S, Weksler B, Noguchi CT. T-cell acute leukemia 1 (TAL1) regulation of erythropoietin receptor and association with excessive erythrocytosis. J Biol Chem. 2012 Oct 26;287(44):36720-31. doi: 10.1074/jbc.M112.378398. Epub 2012 Sep 16. PMID: 22982397; PMCID: PMC3481276.

Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT. Methylation of AR locus does not always reflect X chromosome inactivation state. Blood. 2012 Mar 29;119(13):e100-9. doi: 10.1182/blood-2011-11-390351. Epub 2012 Jan 27. Erratum in: Blood. 2012 Nov 22;120(22):4447. Cairns, Bradley [corrected to Cairns, Bradley R]. PMID: 22286197; PMCID: PMC3321879.

Varricchio L, Tirelli V, Masselli E, Ghinassi B, Saha N, Besmer P, Migliaccio AR. The expression of the glucocorticoid receptor in human erythroblasts is uniquely regulated by KIT ligand: implications for stress erythropoiesis. Stem Cells Dev. 2012 Oct 10;21(15):2852-65. doi: 10.1089/scd.2011.0676. Epub 2012 Jul 9. PMID: 22533504; PMCID: PMC3623384.

Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, Li Y, Schwartz M, Weinberg R, Roda P, Orazi A, Hoffman R. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012 Nov;122(11):3888-99. doi: 10.1172/JCI64397. PMID: 23023702; PMCID: PMC3484080.

Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012 Sep 6;367(10):922-30. doi: 10.1056/NEJMoa1205119. PMID: 22931260; PMCID: PMC3432945.

2011

Duque-Afonso J, Solari L, Essig A, Berg T, Pahl HL, Lübbert M. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. Br J Haematol. 2011 Jun;153(5):612-22. doi: 10.1111/j.1365-2141.2011.08586.x. Epub 2011 Apr 13. PMID: 21488857.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22. PMID: 21860020; PMCID: PMC3236121.

Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, Hoffman R. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genet. 2011 Mar;204(3):165-70. doi: 10.1016/j.cancergencyto.2010.09.001. PMID: 21504717.

Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr;153(1):76-82. doi: 10.1111/j.1365-2141.2011.08582.x. Epub 2011 Feb 17. PMID: 21323890; PMCID: PMC3236079.

Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis. 2011;2011:874146. doi: 10.1155/2011/874146. Epub 2011 Jul 24. PMID: 22084670; PMCID: PMC3200304.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28. PMID: 21712540; PMCID: PMC3186307.

Stein BL, Williams DM, Rogers O, Isaacs MA, Spivak JL, Moliterno AR. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol. 2011 Jan;39(1):95-101. doi: 10.1016/j.exphem.2010.09.008. Epub 2010 Oct 1. PMID: 20888389; PMCID: PMC3004981.

Swierczek SI, Yoon D, Bellanné-Chantelot C, Kim SJ, Saint-Martin C, Delhommeau F, Najman A, Prchal JT. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera. Haematologica. 2011 May;96(5):775-8. doi: 10.3324/haematol.2010.029678. Epub 2011 Jan 27. PMID: 21273266; PMCID: PMC3084927.

Varricchio L, Masselli E, Alfani E, Battistini A, Migliaccio G, Vannucchi AM, Zhang W, Rondelli D, Godbold J, Ghinassi B, Whitsett C, Hoffman R, Migliaccio AR. The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood. 2011 Jul 14;118(2):425-36. doi: 10.1182/blood-2010-07-296921. Epub 2011 Feb 25. PMID: 21355091; PMCID: PMC3138692.

Wang K, Swierczek S, Hickman K, Hakonarson H, Prchal JT. Convergent mechanisms of somatic mutations in polycythemia vera. Discov Med. 2011 Jul;12(62):25-32. PMID: 21794206; PMCID: PMC4347892.

2010

Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM; Myeloproliferative Research Consortium. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol. 2010 Aug;85(8):616-9. doi: 10.1002/ajh.21754. PMID: 20540156; PMCID: PMC2947025.

Bruchova-Votavova H, Yoon D, Prchal JT. miR-451 enhances erythroid differentiation in K562 cells. Leuk Lymphoma. 2010 Apr;51(4):686-93. doi: 10.3109/10428191003629362. PMID: 20218812.

Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 2010 Apr 15;70(8):3402-10. doi: 10.1158/0008-5472.CAN-09-3977. Epub 2010 Apr 13. PMID: 20388788.

Erratum to: Genetic adaptation to extreme hypoxia: Study of high-altitude pulmonary edema in a three-generation Han Chinese family [Blood Cells Mol. Dis. 43:3 (2009) 221-225]. Blood Cells Mol Dis. 2010 Mar 15;44(3):198. doi: 10.1016/j.bcmd.2009.12.008. Erratum for: Blood Cells Mol Dis. 2009 Nov-Dec;43(3):221-5. doi: 10.1016/j.bcmd.2009.04.006. PMID: 20506583; PMCID: PMC3521510.

Ghinassi B, Martelli F, Verrucci M, D'Amore E, Migliaccio G, Vannucchi AM, Hoffman R, Migliaccio AR. Evidence for organ-specific stem cell microenvironments. J Cell Physiol. 2010 May;223(2):460-70. doi: 10.1002/jcp.22055. PMID: 20112287; PMCID: PMC2886205.

Helbing T, Volkmar F, Goebel U, Heinke J, Diehl P, Pahl HL, Bode C, Patterson C, Moser M. Krüppel-like factor 15 regulates BMPER in endothelial cells. Cardiovasc Res. 2010 Feb 1;85(3):551-9. doi: 10.1093/cvr/cvp314. Epub 2009 Sep 17. PMID: 19767294; PMCID: PMC4110462.

Kozma GT, Martelli F, Verrucci M, Gutiérrez L, Migliaccio G, Sanchez M, Alfani E, Philipsen S, Migliaccio AR. Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. Exp Hematol. 2010 Jun;38(6):489-503.e1. doi: 10.1016/j.exphem.2010.03.006. Epub 2010 Mar 18. PMID: 20303380; PMCID: PMC2872687.

Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, Xu M, Hoffman R. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010 Nov 18;116(20):4284-7. doi: 10.1182/blood-2010-04-279125. Epub 2010 Jul 12. PMID: 20625010; PMCID: PMC2993627.

Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010 Jun;38(6):472-80. doi: 10.1016/j.exphem.2010.03.005. Epub 2010 Mar 18. PMID: 20303384; PMCID: PMC4293703.

Migliaccio G, Migliaccio AR. Getting personal with B19 parvovirus. Blood. 2010 Feb 4;115(5):922-3. doi: 10.1182/blood-2009-11-252593. PMID: 20133475.

Migliaccio G, Sanchez M, Masiello F, Tirelli V, Varricchio L, Whitsett C, Migliaccio AR. Humanized culture medium for clinical expansion of human erythroblasts. Cell Transplant. 2010;19(4):453-69. doi: 10.3727/096368909X485049. Epub 2010 Jan 6. PMID: 20149301; PMCID: PMC4397648.

Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, Rossi F, Scudieri AC, Borriello A, Roberti D, Nobili B, Cappellini MD, Oliva A, Amendola G, Migliaccio AR, Mancuso P, Martin-Padura I, Bertolini F, Yoon D, Prchal JT, Della Ragione F. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One. 2010 Aug 5;5(8):e12015. doi: 10.1371/journal.pone.0012015. Retraction in: PLoS One. 2020 Mar 4;15(3):e0230279. doi: 10.1371/journal.pone.0230279. PMID: 20700488; PMCID: PMC2916842.

Roelz R, Pilz IH, Mutschler M, Pahl HL. Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol. 2010 Sep;38(9):792-7. doi: 10.1016/j.exphem.2010.05.005. Epub 2010 May 26. PMID: 20685233.

Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge R. Genetic evidence for high-altitude adaptation in Tibet. Science. 2010 Jul 2;329(5987):72-5. doi: 10.1126/science.1189406. Epub 2010 May 13. PMID: 20466884.

Spivak JL. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008. PMID: 20194236.

Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010 Jul;95(7):1090-7. doi: 10.3324/haematol.2009.014407. Epub 2010 Feb 4. PMID: 20133898; PMCID: PMC2895032.

Teman CJ, Wilson AR, Perkins SL, Hickman K, Prchal JT, Salama ME. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res. 2010 Jul;34(7):871-6. doi: 10.1016/j.leukres.2010.01.005. Epub 2010 Jan 31. PMID: 20122729; PMCID: PMC2875327.

Tripodi J, Hoffman R, Najfeld V, Weinberg R. Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Manag Res. 2010 Sep 17;2:219-23. doi: 10.2147/CMR.S12829. PMID: 21188113; PMCID: PMC3004566.

Varricchio L, Fabucci ME, Alfani E, Godbold J, Migliaccio AR. Compensated variability in the expression of globin-related genes in erythroblasts generated ex vivo from different donors. Transfusion. 2010 Mar;50(3):672-84. doi: 10.1111/j.1537-2995.2009.02483.x. Epub 2009 Nov 4. PMID: 19891622.

Verrucci M, Pancrazzi A, Aracil M, Martelli F, Guglielmelli P, Zingariello M, Ghinassi B, D'Amore E, Jimeno J, Vannucchi AM, Migliaccio AR. CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. J Cell Physiol. 2010 Nov;225(2):490-9. doi: 10.1002/jcp.22228. PMID: 20458749; PMCID: PMC3780594.

Wang W, Schwemmers S, Hexner EO, Pahl HL. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. 2010 Jul 15;116(2):254-66. doi: 10.1182/blood-2009-11-254664. Epub 2010 Mar 25. PMID: 20339092; PMCID: PMC2910609.

Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010 Dec 23;116(26):5972-82. doi: 10.1182/blood-2010-02-269696. Epub 2010 Sep 21. PMID: 20858855; PMCID: PMC3031385.

Zingariello M, Fabucci ME, Bosco D, Migliaccio AR, Martelli F, Rana RA, Zetterberg E. Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation. Biotech Histochem. 2010 Apr 28;85(3):157-70. doi: 10.3109/10520290903149612. PMID: 20426698; PMCID: PMC3700322.

2009

Barosi G, Rosti V. Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol. 2009 Mar;16(2):129-34. doi: 10.1097/MOH.0b013e3283257a9e. PMID: 19468275; PMCID: PMC6368353.

Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009 Jul-Aug;43(1):81-7. doi: 10.1016/j.bcmd.2009.02.001. Epub 2009 Mar 4. PMID: 19264517; PMCID: PMC2693444.

Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009 Aug;88(8):713-9. doi: 10.1007/s00277-009-0758-y. Epub 2009 May 26. PMID: 19468728; PMCID: PMC4135082.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24. PMID: 19559071; PMCID: PMC2746993.

Ghinassi B, Zingariello M, Martelli F, Lorenzini R, Vannucchi AM, Rana RA, Nishikawa M, Migliaccio G, Mascarenhas J, Migliaccio AR. Increased differentiation of dermal mast cells in mice lacking the Mpl gene. Stem Cells Dev. 2009 Sep;18(7):1081-92. doi: 10.1089/scd.2008.0323. PMID: 19025339; PMCID: PMC3135224.

Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009 Apr;41(4):446-9. doi: 10.1038/ng.334. Epub 2009 Mar 15. PMID: 19287382; PMCID: PMC4120192.

Lorenzo VF, Yang Y, Simonson TS, Nussenzveig R, Jorde LB, Prchal JT, Ge RL. Genetic adaptation to extreme hypoxia: study of high-altitude pulmonary edema in a three-generation Han Chinese family. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):221-5. doi: 10.1016/j.bcmd.2009.04.006. Epub 2009 May 29. Erratum in: Blood Cells Mol Dis. 2010 Mar 15;44(3):198. doi: 10.1016/j.bcmd.2009.12.008. PMID: 19481479; PMCID: PMC3506116.

Martelli F, Verrucci M, Migliaccio G, Zingariello M, Rana RA, Vannucchi AM, Migliaccio AR. Removal of the spleen in mice alters the cytokine expression profile of the marrow micro-environment and increases bone formation. Ann N Y Acad Sci. 2009 Sep;1176:77-86. doi: 10.1111/j.1749-6632.2009.04968.x. PMID: 19796235; PMCID: PMC3690574.

Migliaccio AR, Martelli F, Verrucci M, Sanchez M, Valeri M, Migliaccio G, Vannucchi AM, Zingariello M, Di Baldassarre A, Ghinassi B, Rana RA, van Hensbergen Y, Fibbe WE. Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood. 2009 Sep 3;114(10):2107-20. doi: 10.1182/blood-2009-03-211680. Epub 2009 Jul 1. PMID: 19571316; PMCID: PMC2744572.

Migliaccio G, Sanchez M, Leblanc A, Masiello F, Tirelli V, Migliaccio AR, Najfeld V, Whitsett C. Long-term storage does not alter functionality of in vitro generated human erythroblasts: implications for ex vivo generated erythroid transfusion products. Transfusion. 2009 Dec;49(12):2668-79. doi: 10.1111/j.1537-2995.2009.02329.x. Epub 2009 Jul 29. PMID: 19659677.

Migliaccio AR, Whitsett C, Migliaccio G. Erythroid cells in vitro: from developmental biology to blood transfusion products. Curr Opin Hematol. 2009 Jul;16(4):259-68. doi: 10.1097/MOH.0b013e32832bcaa2. PMID: 19444099.

Mutschler M, Magin AS, Buerge M, Roelz R, Schanne DH, Will B, Pilz IH, Migliaccio AR, Pahl HL. NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol. 2009 Jul;146(2):203-17. doi: 10.1111/j.1365-2141.2009.07742.x. Epub 2009 May 19. PMID: 19466964; PMCID: PMC2749484.

Rotili D, Simonetti G, Savarino A, Palamara AT, Migliaccio AR, Mai A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies. Curr Top Med Chem. 2009;9(3):272-91. doi: 10.2174/156802609788085296. PMID: 19355991.

Seaman V, Jumaan A, Yanni E, Lewis B, Neyer J, Roda P, Xu M, Hoffman R. Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):534-40. doi: 10.1158/1055-9965.EPI-08-0922. Epub 2009 Feb 3. PMID: 19190168.

Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009 May 21;113(21):5246-9. doi: 10.1182/blood-2008-11-191544. Epub 2009 Mar 17. PMID: 19293426; PMCID: PMC2686192.

Sozer S, Ishii T, Fiel MI, Wang J, Wang X, Zhang W, Godbold J, Xu M, Hoffman R. Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):304-12. doi: 10.1016/j.bcmd.2009.08.005. Epub 2009 Sep 16. PMID: 19762257.

Stellacci E, Di Noia A, Di Baldassarre A, Migliaccio G, Battistini A, Migliaccio AR. Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72. doi: 10.1016/j.exphem.2009.02.005. PMID: 19375647; PMCID: PMC2689622.

Varricchio L, Mancini A, Migliaccio AR. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. 2009 Jun 1;2(3):315-334. doi: 10.1586/ehm.09.17. PMID: 20352017; PMCID: PMC2845468.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15. PMID: 19615425.

Wang X, Zhang W, Ishii T, Sozer S, Wang J, Xu M, Hoffman R. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res. 2009 Oct 1;69(19):7612-8. doi: 10.1158/0008-5472.CAN-09-1823. Epub 2009 Sep 14. PMID: 19752087; PMCID: PMC3234420.

Ye Z, Zhan H, Mali P, Dowey S, Williams DM, Jang YY, Dang CV, Spivak JL, Moliterno AR, Cheng L. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009 Dec 24;114(27):5473-80. doi: 10.1182/blood-2009-04-217406. Epub 2009 Oct 1. PMID: 19797525; PMCID: PMC2798863.

2008

Agarwal N, Prchal JT. Erythropoietic agents and the elderly. Semin Hematol. 2008 Oct;45(4):267-75. doi: 10.1053/j.seminhematol.2008.06.007. PMID: 18809098; PMCID: PMC2643059.

Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653. PMID: 18166784.

Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdilès MC, Barosi G, Vannucchi AM; Myeloproliferative Disorders Research Consortium. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008 Aug;26(8):1920-30. doi: 10.1634/stemcells.2008-0377. Epub 2008 May 29. PMID: 18511598.

Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica. 2008 Jul;93(7):1009-16. doi: 10.3324/haematol.12706. Epub 2008 May 27. PMID: 18508790.

Cario H, Schwarz K, Herter JM, Komrska V, McMullin MF, Minkov M, Niemeyer C, Pospisilova D, Reinhard H, Debatin KM, Pahl HL. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol. 2008 Aug;142(4):622-6. doi: 10.1111/j.1365-2141.2008.07220.x. Epub 2008 Jun 28. PMID: 18557746; PMCID: PMC4120186.

Chunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 2008 Oct;93(10):1593-5. doi: 10.3324/haematol.13203. Epub 2008 Jul 18. PMID: 18641018.

Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, Akard LP, Hoffman R, Rondelli D. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol. 2008 Apr;141(1):80-3. doi: 10.1111/j.1365-2141.2008.07010.x. PMID: 18324970.

Martelli F, Ghinassi B, Lorenzini R, Vannucchi AM, Rana RA, Nishikawa M, Partamian S, Migliaccio G, Migliaccio AR. Thrombopoietin inhibits murine mast cell differentiation. Stem Cells. 2008 Apr;26(4):912-9. doi: 10.1634/stemcells.2007-0777. Epub 2008 Feb 14. PMID: 18276801; PMCID: PMC2741730.

Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, Hoffman R. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008 Feb;36(2):158-71. doi: 10.1016/j.exphem.2007.10.001. PMID: 18206727; PMCID: PMC2747096.

Migliaccio AR, Rotili D, Nebbioso A, Atweh G, Mai A. Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia. Int J Biochem Cell Biol. 2008;40(11):2341-7. doi: 10.1016/j.biocel.2008.04.024. Epub 2008 May 29. PMID: 18617435; PMCID: PMC2581454.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23. PMID: 18723264; PMCID: PMC2600434.

Samuelson SJ, Prchal JT. Pediatric essential thrombocythemia (ET) from the Czech Republic. Leuk Res. 2008 Mar;32(3):367-8. doi: 10.1016/j.leukres.2007.07.025. Epub 2007 Sep 7. PMID: 17825908; PMCID: PMC2410082.

Sozer S, Wang X, Zhang W, Fiel MI, Ishii T, Wang J, Wisch N, Xu M, Hoffman R. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Mol Dis. 2008 Nov-Dec;41(3):284-91. doi: 10.1016/j.bcmd.2008.06.008. Epub 2008 Aug 19. PMID: 18715806.

Swierczek SI, Agarwal N, Nussenzveig RH, Rothstein G, Wilson A, Artz A, Prchal JT. Hematopoiesis is not clonal in healthy elderly women. Blood. 2008 Oct 15;112(8):3186-93. doi: 10.1182/blood-2008-03-143925. Epub 2008 Jul 18. PMID: 18641369; PMCID: PMC2569172.

Zetterberg E, Popat U, Hasselbalch H, Prchal J, Palmblad J. Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica. 2008 Jun;93(6):945-6. doi: 10.3324/haematol.12426. Epub 2008 May 6. PMID: 18460649.

2007

Agarwal N, Gordeuk RV, Prchal JT. Genetic mechanisms underlying regulation of hemoglobin mass. Adv Exp Med Biol. 2007;618:195-210. doi: 10.1007/978-0-387-75434-5_15. PMID: 18269198.

Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007 Nov;35(11):1657-67. doi: 10.1016/j.exphem.2007.08.021. PMID: 17976518; PMCID: PMC2699372.

Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood. 2007 Sep 1;110(5):1411-9. doi: 10.1182/blood-2006-09-018655. Epub 2007 Apr 13. PMID: 17435115; PMCID: PMC1975831.

Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007 Aug 1;110(3):986-93. doi: 10.1182/blood-2006-12-064626. Epub 2007 May 1. PMID: 17473062; PMCID: PMC1924766.

El-Moneim AA, Kratz CP, Böll S, Rister M, Pahl HL, Niemeyer CM. Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Cancer. 2007 Jul;49(1):52-5. doi: 10.1002/pbc.21128. PMID: 17171694.

Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol. 2007 Apr;35(4):587-95. doi: 10.1016/j.exphem.2006.12.007. PMID: 17379069; PMCID: PMC1931508.

Gaikwad A, Prchal JT. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Nov;35(11):1647-56. doi: 10.1016/j.exphem.2007.08.018. PMID: 17976517; PMCID: PMC2206678.

Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun;35(6):931-8. doi: 10.1016/j.exphem.2007.03.012. PMID: 17533047.

Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio G, Orkin SH, Migliaccio AR. The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood. 2007 Feb 15;109(4):1460-71. doi: 10.1182/blood-2006-07-030726. Epub 2006 Oct 12. PMID: 17038527; PMCID: PMC1794062.

Ghinassi B, Verrucci M, Jelicic K, Di Noia A, Migliaccio G, Migliaccio AR. Interleukin-3 and erythropoietin cooperate in the regulation of the expression of erythroid-specific transcription factors during erythroid differentiation. Exp Hematol. 2007 May;35(5):735-47. doi: 10.1016/j.exphem.2007.02.007. PMID: 17577923.

Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72. doi: 10.1016/j.bbmt.2006.11.003. PMID: 17222772.

Hu WY, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, Bruno E, Hoffman R, Xu M. Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br J Haematol. 2007 May;137(4):378-9. doi: 10.1111/j.1365-2141.2007.06572.x. Epub 2007 Apr 4. PMID: 17408398.

Ishii T, Xu M, Zhao Y, Hu WY, Ciurea S, Bruno E, Hoffman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia. 2007 Feb;21(2):373-4. doi: 10.1038/sj.leu.2404475. Epub 2006 Nov 23. PMID: 17122864.

Ishii T, Zhao Y, Shi J, Sozer S, Hoffman R, Xu M. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. Leukemia. 2007 Dec;21(12):2433-41. doi: 10.1038/sj.leu.2404899. Epub 2007 Aug 16. PMID: 17713553.

Ishii T, Zhao Y, Sozer S, Shi J, Zhang W, Hoffman R, Xu M. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol. 2007 Nov;35(11):1633-40. doi: 10.1016/j.exphem.2007.07.005. Epub 2007 Aug 30. PMID: 17764815.

Mai A, Jelicic K, Rotili D, Di Noia A, Alfani E, Valente S, Altucci L, Nebbioso A, Massa S, Galanello R, Brosch G, Migliaccio AR, Migliaccio G. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol. 2007 Nov;72(5):1111-23. doi: 10.1124/mol.107.036772. Epub 2007 Jul 31. PMID: 17666592.

Migliaccio AR, Rana RA, Vannucchi AM, Manzoli FA. Role of thrombopoietin in mast cell differentiation. Ann N Y Acad Sci. 2007 Jun;1106:152-74. doi: 10.1196/annals.1392.024. Epub 2007 Apr 27. PMID: 17468237.

Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol. 2007 Nov;35(11):1668-76. doi: 10.1016/j.exphem.2007.08.025. PMID: 17976519.

Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, Prchal JT. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007 Jan;35(1):32-8. doi: 10.1016/j.exphem.2006.11.012. PMID: 17198871.

Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia. 2007 Oct;21(10):2210-2. doi: 10.1038/sj.leu.2404755. Epub 2007 May 17. PMID: 17507997.

Rives S, Pahl HL, Florensa L, Bellosillo B, Neusuess A, Estella J, Debatin KM, Kohne E, Schwarz K, Cario H. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica. 2007 May;92(5):674-7. doi: 10.3324/haematol.10787. PMID: 17488692.

Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G; Italian Registry of Myelofibrosis with Myeloid Metaplasia; Myeloproliferative Disorders Research Consortium. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6. doi: 10.1016/j.bcmd.2007.01.003. Epub 2007 Mar 9. PMID: 17350297.

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol. 2007 Nov;35(11):1695-703. doi: 10.1016/j.exphem.2007.07.004. Epub 2007 Aug 30. PMID: 17764814; PMCID: PMC2270411.

Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007 Jul 1;67(13):6417-24. doi: 10.1158/0008-5472.CAN-07-0572. PMID: 17616702.

Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G, Heimpel H, Pahl HL. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol. 2007 Apr;86(4):239-44. doi: 10.1007/s00277-006-0214-1. Epub 2007 Jan 26. PMID: 17256145.

Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007 Nov;35(11):1641-6. doi: 10.1016/j.exphem.2007.08.010. Epub 2007 Oct 17. PMID: 17920755; PMCID: PMC2149910.

Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007 Mar 1;109(5):1801-9. doi: 10.1182/blood-2006-08-043471. Epub 2006 Oct 19. PMID: 17053059; PMCID: PMC1801067.

2006

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900. PMID: 16639737.

Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006 Sep;91(9):1281-2. PMID: 16956836.

2005

Goerttler PL, März E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, Marchioli R, Spivak JL, Pahl HL; MPD Research Consortium. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica. 2005 Jun;90(6):851-3. PMID: 15951300.

Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood. 2005 Oct 15;106(8):2862-4. doi: 10.1182/blood-2005-04-1515. Epub 2005 Jun 28. PMID: 15985544.